10-Q: Denali Capital Acquisition Corp. Reports Net Loss for Q1 2025, Faces Nasdaq Delisting

Denali Capital Acquisition Corp. reports a net loss for the first quarter of 2025 and is addressing its Nasdaq delisting while pursuing a business combination with Semnur Pharmaceuticals.

Summary

• Denali Capital Acquisition Corp. reported a net loss of $194,603 for the quarter ended March 31, 2025, compared to a net income of $264,330 for the same period in 2024.
• The company's operating loss for the quarter was $246,600, driven by formation and operating costs.
• Interest income from the trust account partially offset the losses, amounting to $78,971.
• The company is pursuing a business combination with Semnur Pharmaceuticals, with an equity value of $2.5 billion.
• Denali Capital Acquisition Corp. received a delisting notice from Nasdaq due to non-compliance with listing rules and has since begun trading on the OTC markets.
• The company's shareholders approved an extension to complete a business combination until December 11, 2025.
• The company has issued convertible promissory notes to its sponsor and other parties to fund operations and extend the business combination deadline.
• As of March 31, 2025, the company had $2,736 in cash outside of the trust account and a working capital deficit of $7,848,981.
• The company's management believes that it may not have sufficient working capital to meet its needs through the consummation of the initial business combination.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reported net loss, Nasdaq delisting, and concerns about working capital. However, the ongoing efforts to complete the business combination with Semnur and the extension approved by shareholders provide some positive outlook.

Positives

• The company is actively pursuing a business combination with Semnur Pharmaceuticals.
• Shareholders approved an extension to complete the business combination, providing additional time to finalize the deal.
• Interest income from the trust account partially offset operating losses.
• The company has secured funding through convertible promissory notes to support operations.

Negatives

• The company reported a net loss of $194,603 for Q1 2025.
• Denali Capital Acquisition Corp. received a Nasdaq delisting notice and began trading on the OTC markets.
• The company has a significant working capital deficit of $7,848,981.
• Management expresses doubt about having sufficient working capital to meet its needs through the consummation of the initial business combination.

Risks

• The company faces the risk of not completing the business combination within the extended timeframe.
• The company's delisting from Nasdaq could negatively impact investor confidence and stock value.
• The company's ability to continue as a going concern is dependent on completing the business combination or securing additional financing.
• The company's reliance on convertible promissory notes for funding could increase its debt burden.
• The ongoing military action in Ukraine and hostilities in the Middle East could have an adverse impact on the company's financial condition.

Future Outlook

The company is focused on completing its business combination with Semnur Pharmaceuticals and is working to address its Nasdaq delisting. Management expresses doubt about having sufficient working capital to meet its needs through the consummation of the initial business combination.

Industry Context

The report reflects the challenges faced by SPACs in finding and completing business combinations, particularly in a volatile market environment. The delisting from Nasdaq and the need for extensions highlight the difficulties in meeting regulatory requirements and timelines.

Comparison to Industry Standards

• Given the lack of operational activity, comparing Denali to industry standards is difficult.
• However, the financial metrics can be compared to other SPACs that are in the pre-combination phase.
• For example, other SPACs such as Gores Metropoulos II, Inc. and Churchill Capital Corp VII have faced similar challenges in completing business combinations and maintaining listing compliance.
• The high redemption rates experienced by Denali are also common among SPACs, reflecting investor uncertainty and the desire for a return of capital.

Related Party Transactions

• The company has issued convertible promissory notes to its sponsor to fund operations.
• Scilex agreed to purchase 500,000 Class B ordinary shares from the sponsor.

Stakeholder Impact

• Shareholders face uncertainty due to the Nasdaq delisting and the company's financial condition.
• Employees' job security is dependent on the successful completion of the business combination.
• Creditors face the risk of non-payment if the company is unable to complete the business combination or secure additional financing.

Next Steps

• The company needs to complete the business combination with Semnur Pharmaceuticals.
• The company needs to regain compliance with listing requirements or successfully operate on the OTC markets.
• The company needs to secure additional financing to support operations and complete the business combination.

Key Dates

Keywords

business combination, Semnur Pharmaceuticals, SPAC, delisting, convertible notes, trust account, liquidity, Denali Capital, financial results, OTC markets